Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Seniz Ongoren, Ahmet Emre Eskazan, Veysel Suzan, Sercan Savci, Isil Erdogan Ozunal, Selin Berk, Fevzi Fırat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Yucel Erbilgin, Sibel Aylin Iseri, Muhlis Cem Ar, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek & Teoman Soysal. (2018) Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology 23:4, pages 212-220.
Read now
Read now
Dilek Keskin, Sevil Sadri & Ahmet Emre Eskazan. (2016) Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Design, Development and Therapy 10, pages 3355-3361.
Read now
Read now
Onur Kirkizlar & Ahmet Emre Eskazan. (2016) Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Review of Quality of Life in Cancer Care 1:5, pages 353-359.
Read now
Read now
Stephen Harnicar & Sherry Mathew. (2014) Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 61-67.
Read now
Read now
Articles from other publishers (17)
Gianantonio Rosti, Tim H. Brümmendorf, Björn T. Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo Gambacorti-Passerini, Thomas Ernst, Huadong Zhao, Luke Kuttschreuter, Simon Purcell, Francis J. Giles & Andreas Hochhaus. (2023) Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia.
Crossref
Crossref
Guray Saydam, Ali Unal, Ibrahim Celalettin Haznedaroglu, Abdullah Hacihanifioglu, Ozgur Mehtap, Erdal Kurtoglu, Mesut Gocer, Mehmet Turgut, Engin Kelkitli, Memis Hilmi Atay, Nil Guler, Basak Unver Koluman, Mehmet Sonmez, Nergiz Erkut, Emin Kaya, Irfan Kuku, Mehmet Ali Erkurt, Gulsum Ozet, Funda Ceran, Fahri Sahin, Nur Soyer, Meliha Nalcaci, Mehmet Yilmaz, Sirac Bozkurt, Birkan Aver, Begum Ozdengulsun, Egemen Ozbilgili & Osman Ilhan. (2022) Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. International Journal of Hematologic Oncology 11:3.
Crossref
Crossref
Ahmet Emre Eşkazan. (2021) A clinical appraisal of chronic myeloid leukaemia (CML)‐related death and CML‐specific death—Are they synonymous?. International Journal of Clinical Practice 75:6.
Crossref
Crossref
Carlo Gambacorti-Passerini, Philipp le Coutre & Rocco Piazza. (2020) The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncology 16:2, pages 4395-4408.
Crossref
Crossref
Michael J Reff, Alexandra Shillingburg, Bhavesh Shah, Christopher Elder, Hillary Prescott & Julie Kennerly-Shah. (2019) Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations. Journal of Oncology Pharmacy Practice 26:1, pages 156-174.
Crossref
Crossref
Valentín García-Gutiérrez & Juan Carlos Hernández-Boluda. (2019) Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. Frontiers in Oncology 9.
Crossref
Crossref
Yufeng Li, Chun-ling Wang, Banhe Din, Liang Yu & Jiabin Zhu. (2017) Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy. Acta Haematologica 137:3, pages 158-162.
Crossref
Crossref
Paul W. Manley & Nikolaus J. Stiefl. 2018. Cancer II. Cancer II
1
37
.
Roberto Latagliata, Fabio Stagno, Mario Annunziata, Elisabetta Abruzzese, Alessandra Iurlo, Attilio Guarini, Carmen Fava, Antonella Gozzini, Massimiliano Bonifacio, Federica Sorà, Sabrina Leonetti Crescenzi, Monica Bocchia, Monica Crugnola, Fausto Castagnetti, Isabella Capodanno, Sara Galimberti, Costanzo Feo, Raffaele Porrini, Patrizia Pregno, Manuela Rizzo, Agostino Antolino, Endri Mauro, Nicola Sgherza, Luigiana Luciano, Mario Tiribelli, Antonella Russo Rossi, Malgorzata Trawinska, Paolo Vigneri, Massimo Breccia, Gianantonio Rosti & Giuliana Alimena. (2016) Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia 18:9, pages 536-540.
Crossref
Crossref
Tom Fleischer, Tung‐Ti Chang, Jen‐Huai Chiang, Ching‐Mao Chang, Ching‐Yun Hsieh & Hung‐Rong Yen. (2016) Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: a nationwide population‐based cohort study. Cancer Medicine 5:4, pages 640-648.
Crossref
Crossref
Tim H. Brümmendorf, Jorge E. Cortes, Hanna J. Khoury, Hagop M. Kantarjian, Dong‐Wook Kim, Philippe Schafhausen, Maureen G. Conlan, Mark Shapiro, Kathleen Turnbull, Eric Leip, Carlo Gambacorti‐Passerini & Jeff H. Lipton. (2015) Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology 172:1, pages 97-110.
Crossref
Crossref
F. Efficace, G. Rosti, M. Breccia, F. Cottone, J. M. Giesinger, F. Stagno, A. Iurlo, A. Russo Rossi, L. Luciano, B. Martino, S. Galimberti, D. Turri, M. Bergamaschi, M. Tiribelli, C. Fava, E. Angelucci, F. Mandelli & M. Baccarani. (2015) The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Annals of Hematology 95:2, pages 211-219.
Crossref
Crossref
Delphine Rea. 2016. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
71
87
.
Susanne SaußeleMarie-Paloma KraußRüdiger HehlmannMichael LausekerUlrike ProetelLida KalmantiBenjamin HanfsteinAlice FabariusDoris KraemerWolfgang E. BerdelMartin BentzPeter StaibMaike de WitMartin WernliFlorian ZettlHolger F. HebartMarkus HahnJochen HeymannsIngo Schmidt-WolfNorbert SchmitzMichael J. EckartWinfried GassmannAndrea BartholomäusAntonio PezzuttoElisabeth Oppliger LeibundgutDominik HeimStefan W. KrauseAndreas Burchert, Wolf-Karsten HofmannJoerg HasfordAndreas Hochhaus, Markus PfirrmannMartin C. Müller. (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood 126:1, pages 42-49.
Crossref
Crossref
Delphine Rea. (2015) Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Annals of Hematology 94:S2, pages 149-158.
Crossref
Crossref
Mario Tiribelli & Marta Medeot. (2014) Overcoming therapy failure in elderly patients with chronic myeloid leukemia. International Journal of Hematologic Oncology 3:5, pages 353-365.
Crossref
Crossref
Gabriele Gugliotta, Fausto Castagnetti, Michela Apolinari, Sara Pirondi, Michele Cavo, Michele Baccarani & Gianantonio Rosti. (2014) First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies. Drugs 74:6, pages 627-643.
Crossref
Crossref